AU7634694A - Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same - Google Patents

Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same

Info

Publication number
AU7634694A
AU7634694A AU76346/94A AU7634694A AU7634694A AU 7634694 A AU7634694 A AU 7634694A AU 76346/94 A AU76346/94 A AU 76346/94A AU 7634694 A AU7634694 A AU 7634694A AU 7634694 A AU7634694 A AU 7634694A
Authority
AU
Australia
Prior art keywords
bridged
methods
preparing same
oligonucleotide conjugates
polycationic polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU76346/94A
Inventor
Stanley Stein
Ching-Hsuan Tung
Ziping Wei
Tianmin Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Medicine and Dentistry of New Jersey
Original Assignee
University of Medicine and Dentistry of New Jersey
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Medicine and Dentistry of New Jersey, Rutgers State University of New Jersey filed Critical University of Medicine and Dentistry of New Jersey
Publication of AU7634694A publication Critical patent/AU7634694A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
AU76346/94A 1993-08-20 1994-08-18 Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same Abandoned AU7634694A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11011493A 1993-08-20 1993-08-20
US110114 1993-08-20
PCT/US1994/009402 WO1995006056A1 (en) 1993-08-20 1994-08-18 Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same

Publications (1)

Publication Number Publication Date
AU7634694A true AU7634694A (en) 1995-03-21

Family

ID=22331291

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76346/94A Abandoned AU7634694A (en) 1993-08-20 1994-08-18 Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same

Country Status (2)

Country Link
AU (1) AU7634694A (en)
WO (1) WO1995006056A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6011496A (en) * 1995-06-08 1997-01-09 Therexsys Limited Improved pharmaceutical compositions for gene therapy
TNSN99224A1 (en) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc METHODS OF REDUCING GLUCOSE AND TRIGLYCERIDE LEVELS IN SERUM AND FOR ANTIGENESIS SUPPRESSION USING INDOLEALKANOIC ACIDS
US6855817B2 (en) 2000-07-21 2005-02-15 Mark B. Lyles Materials and methods for binding nucleic acids to surfaces
WO2002022711A2 (en) * 2000-08-18 2002-03-21 University Of North Carolina At Chapel Hill Compositions of nucleic acids that form molten phases and methods of use thereof
CA2436857A1 (en) * 2000-12-14 2002-06-20 Gen-Probe Incorporated Method and kit for enhancing the association rates of polynucleotides
US6919180B2 (en) * 2002-03-22 2005-07-19 Sigma Genosys, L.P. Hybridization rate enhancement for substrate-bound specific nucleic acid-binding agents
DE102004021584A1 (en) * 2004-05-03 2005-12-01 Stefan Kochanek New viral vector particle comprising capsid proteins comprising an attachment site comprising cysteine residue, useful in preparing a composition for treating e.g., tumor
US7776322B2 (en) 2004-08-16 2010-08-17 Stefan Kochanek Modified viral vector particles
CA2669914C (en) 2006-11-16 2017-11-07 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
US8283384B2 (en) 2008-01-24 2012-10-09 University Of Utah Research Foundation Adhesive complex coacervates and methods of making and using thereof
JP5530934B2 (en) 2008-01-24 2014-06-25 ユニバーシティ オブ ユタ リサーチ ファンデーション Adhesive composite coacervate and methods of making and using the same
KR20110097938A (en) * 2008-12-11 2011-08-31 싸이오서스 테라퓨틱스 엘티디. Modification of nucleic acid vectors with polymers comprising charged quaternary amino groups
CA2788998A1 (en) * 2010-02-26 2011-09-01 University Of Utah Research Foundation Adhesive complex coacervates produced from electrostatically associated block copolymers and methods for making and using the same
EP2575906B1 (en) 2010-05-24 2014-12-10 University of Utah Research Foundation Reinforced adhesive complex coacervates and methods of making and using thereof
US9173971B2 (en) 2010-11-12 2015-11-03 University Of Utah Research Foundation Simple adhesive coacervates and methods of making and using thereof
DK2717896T3 (en) 2011-06-08 2016-12-19 Kai Pharmaceuticals Inc Therapeutics for regulating phoshor serum
EP2953992B1 (en) 2013-02-06 2021-11-24 3M Innovative Properties Company Polymers, preparation and use thereof
JP6825914B2 (en) * 2014-05-23 2021-02-03 ジェンザイム・コーポレーション Multiple oligonucleotide moieties on peptide carriers
CA2955048C (en) 2014-07-14 2020-11-03 University Of Utah Research Foundation In situ solidifying compositions and methods of making and using therof
US11896234B2 (en) 2018-01-26 2024-02-13 Fluidx Medical Technology, Llc Apparatus and method of using in situ solidifying complex coacervates for vascular occlusion

Also Published As

Publication number Publication date
WO1995006056A1 (en) 1995-03-02

Similar Documents

Publication Publication Date Title
AU7634694A (en) Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
AU7600496A (en) Interferon-polymer conjugates and process for preparing the same
AU2591697A (en) Oil-sorbing article and methods for making and using same
AU2819795A (en) Locking universal support arm
AU4781297A (en) Vaccines
AU3447593A (en) Beverage preparing assemblies
EP0690494A3 (en) Connection and build-up-process for multi-chip-modules
AU1581997A (en) Inverting bag co-dispenser
AU4191096A (en) Locking device
AU2224297A (en) Databases
AU2116995A (en) Cyclic polycationic polymer-oligonucleotide conjugates and methods for preparing same
AU3016495A (en) Sealed article
AU2911597A (en) Sealed article
AU2464797A (en) Baby carrier
AU2025395A (en) Sustained release preparations
AU7571194A (en) Azotobacterin and the method for preparing the same
AU4068197A (en) Brazing and preparing articles for brazing
AU2035997A (en) Sealant-carrying articles
AU8436191A (en) Securing device
AU7997794A (en) Improvements in connecting means
AU1738497A (en) Lockable coupling
AU2172097A (en) Infusion packages and methods for their manufacture
AU3945493A (en) Paired-ion oligonucleotides and methods for preparing same
AU5009993A (en) Isoprostane-protein conjugates
AU3488895A (en) Carrier device